Weight loss drugs can halve heart patients' risk of early death, study finds
GLP-1 agonist weight-loss drugs substantially reduce hospitalization and premature death risk in obese heart failure patients with type 2 diabetes, up to 58%.
Novo Nordisk, creator of the mega-hit drug Ozempic, has seen a loss of nearly $100 billion in market value due to collapsing sales and missed forecasts.
Doctors Are Warning That Ozempic's Severe Side Effects May Outweigh Its Benefits
GLP-1 weight loss drugs like Ozempic and Wegovy have concerning side effects, including potential vision impairment and increased risk of kidney problems.
Obesity drugs show promise treating a new ailment: migraine
In a small study, the drug liraglutide reduced monthly migraine episodes by nearly half among people with obesity who experience the headache-inducing condition.
